

## Update

---

Universal Biosensors, Inc. (ASX: UBI) advises:

- Sales orders in December are forecast to exceed \$1,000,000 (unaudited estimate).
- UBI has received its largest order for Xprecia Prime devices from India. The order is for 520 devices, which are to be delivered in December.
- UBI submitted its full response to the FDA’s “Request for Additional Information” on 23 November. Assuming there are no further queries, an FDA decision re the approval of Xprecia Prime for sale in the USA is expected during Q1 2024.

Mr John Sharman, CEO of UBI said; “December is forecast to be UBI’s biggest revenue month ever and is the first time we expect to record \$1,000,000 from selling our products directly to customers (excluding Siemens). Six of UBI’s new products have been in the market for approximately 6 months and sales growth during H2 2023 has been strong (compared with H1 2023). We now have 11 revenue generating products in market and we are starting to build sales momentum.”

**End**

***Announcement authorised by the Board of Directors of Universal Biosensors, Inc.***

For further information contact:

John Sharman  
Chief Executive Officer  
+61 (0) 414 440 680

**End**

### **About Xprecia Prime™**

The Xprecia Prime™ Coagulation Analyzer is Universal Biosensors second generation, new and improved coagulation monitoring device. Xprecia Prime™ fits into your palm; is portable, accurate and easy to use. The device is designed for fast and reliable prothrombin time (PT) results displayed in seconds and International Normalised Ratio (INR). It is used to monitor the dosage of vitamin K antagonists in patients to ensure its safety and efficacy. Dangerous bleeding events can occur if the ideal dosage of the drug is exceeded, while if the dosage is lower than required the patient is at risk of thrombosis. The prothrombin time (PT) test allows physicians to appropriately adjust the patient's dose of the drug to compensate for any diet and lifestyle changes. Globally, approximately 10 million patients are taking warfarin, and over 300 million PT/INR tests are conducted annually to monitor the safe and effective dosage of anticoagulants, representing a major market opportunity for Xprecia Prime™. For additional information visit: <https://www.universalbiosensors.com/products/xprecia/>

### **About Universal Biosensors**

Universal Biosensors, founded in 2001, specialises in the design and development of electrochemical cells (strips) used in conjunction with point of use devices that are used in various industries such as healthcare (point of care), wine, food, and agriculture. UBI's ambition is to build a multi product stable of biosensors in large markets which generate ongoing revenue streams. For additional information regarding Universal Biosensors, Inc., refer to: <http://www.universalbiosensors.com>.

### **Forward-Looking Statements**

The statements contained in this release that are not purely historical are forward-looking statements within the meaning of the US Securities Exchange Act of 1934. Forward-looking statements in this release include statements regarding our expectations, beliefs, hopes, intentions or strategies. All forward-looking statements included in this release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. Our actual results could differ materially from our current expectations. We cannot assure you when, if at all, the proposals outlined in this release will occur, and the terms of any such proposal are subject to change. Factors that could cause or contribute to such differences include, but are not limited to, factors and risks disclosed from time to time in reports filed with the SEC.